Bicara Therapeutics (BCAX) Accounts Payables (2023 - 2026)
Bicara Therapeutics (BCAX) posted quarterly Accounts Payables of $6.2 million for Q1 2026, up 162.76% year-over-year from $2.4 million in Q1 2025, and up 1447.0% quarter-over-quarter from $400000.0 in Q4 2025.
Bicara Therapeutics (BCAX) Accounts Payables (2023 - 2026) Analysis & Trends
Bicara Therapeutics' Accounts Payables history runs 4 years deep, the most recent figure standing at $6.2 million for Q1 2026.
- In Q1 2026, Accounts Payables rose 162.76% year-over-year to $6.2 million; the TTM figure through Mar 2026 stood at $6.2 million (up 162.76% YoY), while the FY2025 annual figure was $400000.0, down 34.96% from the prior year.
- Accounts Payables for Q1 2026 stood at $6.2 million, up from $400000.0 in the prior quarter.
- The five-year high for Accounts Payables was $6.2 million in Q1 2026, with the low at $400000.0 in Q4 2025.
- The 4-year median for Accounts Payables is $900000.0 (2023), against an average of $1.7 million.
- The sharpest annual moves came in 2024 and 2026: Accounts Payables plunged 38.5% in 2024, then jumped 162.76% in 2026.
- Bicara Therapeutics' Accounts Payables stood at $1.0 million in 2023, then slumped by 38.5% to $615000.0 in 2024, then slumped by 34.96% to $400000.0 in 2025, then surged by 1447.0% to $6.2 million in 2026.
- Business Quant data shows BCAX's Accounts Payables at $6.2 million in Q1 2026, $400000.0 in Q4 2025, and $1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Bicara Therapeutics | 1.60 Bn | 1.60 Bn | - | 7.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.43 Mn |
| Mar 31, 2026 | 6.19 Mn |
| Dec 31, 2025 | 400,000.00 |
| Sep 30, 2025 | 1.20 Mn |
| Jun 30, 2025 | 800,000.00 |
| Mar 31, 2025 | 2.36 Mn |
| Dec 31, 2024 | 615,000.00 |
| Sep 30, 2024 | 800,000.00 |
| Dec 31, 2023 | 1.00 Mn |